| Characteristics of the study population | Recurrence | No recurrence | value |
| Male, (%) | 9 (47) | 21 (43) | 0.61 | Age (years), median (IQR) | 62 (55, 72) | 63 (51, 74) | 0.73 | BMI (kg/m2), median (IQR) | 27.8 (25, 30.8) | 26.8 (23.6, 30.9) | 0.32 | IFG or diabetes, (%) | 2 (11) | 9 (18) | 0.44 | WBC(×103/mm3), median (IQR) | 10.3 (7.1, 12.5) | 11.30 (6.6, 12.8) | 0.95 | Creatinine (mg/dL), median (IQR) | 0.90 (0.80, 1.01) | 0.97 (0.78, 1.38) | 0.43 | Albumin (g/dL), median (IQR) | 3.45 (2.95, 4.40) | 3.50 (3.10, 4.10) | 0.92 | Antibiotic prescribed within 8 weeks prior to CDI, (%) | 18 (95) | 35 (71) | 0.038 | Antibiotic prescribed within 4 weeks prior to CDI, (%) | 17 (89) | 25 (51) | 0.003 | Prescribed proton pump inhibitor, (%) | 2 (11) | 10 (20) | 0.35 | Prescribed H2 blocker, (%) | 1 (5.3) | 4 (8.2) | 0.69 | Admitted to hospital, (%) | 12 (63) | 25 (51) | 0.38 | Days of hospitalization, median (IQR) | 3.5 (3.50, 5.25) | 4.0 (3.0, 4.0) | 0.59 | Initial treatment with metronidazole, (%) | 16 (84) | 41 (84) | 0.50 | Initial treatment with vancomycin, (%) | 2 (11) | 8 (16) | 0.33 | Initial treatment with metronidazole and vancomycin, (%) | 1 (5.3) | 0 (0) | 0.054 |
|
|